Literature DB >> 30867572

Immunotherapy for glioblastoma: quo vadis?

Michael Weller1, Emilie Le Rhun2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30867572     DOI： 10.1038/s41571-019-0195-3

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?

Authors:  Thomas N Seyfried; Laura Shelton; Gabriel Arismendi-Morillo; Miriam Kalamian; Ahmed Elsakka; Joseph Maroon; Purna Mukherjee
Journal:  Neurochem Res       Date:  2019-04-25       Impact factor: 3.996

2.  Knockdown of T Cell Immunoglobulin and Mucin 1 (Tim-1) Suppresses Glioma Progression Through Inhibition of the Cytokine-PI3K/AKT Pathway.

Authors:  Peng Zhou; Maoxing Fei; Yanling Han; Mengliang Zhou; Handong Wang
Journal:  Onco Targets Ther       Date:  2020-08-04       Impact factor: 4.147

Review 3.  Advances in local therapy for glioblastoma - taking the fight to the tumour.

Authors:  Thomas S van Solinge; Lisa Nieland; E Antonio Chiocca; Marike L D Broekman
Journal:  Nat Rev Neurol       Date:  2022-03-11       Impact factor: 44.711

Review 4.  Metabolic management of microenvironment acidity in glioblastoma.

Authors:  Thomas N Seyfried; Gabriel Arismendi-Morillo; Giulio Zuccoli; Derek C Lee; Tomas Duraj; Ahmed M Elsakka; Joseph C Maroon; Purna Mukherjee; Linh Ta; Laura Shelton; Dominic D'Agostino; Michael Kiebish; Christos Chinopoulos
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

Review 5.  The immune landscape of common CNS malignancies: implications for immunotherapy.

Authors:  Martina Ott; Robert M Prins; Amy B Heimberger
Journal:  Nat Rev Clin Oncol       Date:  2021-06-11       Impact factor: 66.675

6.  Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies.

Authors:  Chisato Yokota; Jun Nakata; Koji Takano; Hiroko Nakajima; Hiromu Hayashibara; Hikaru Minagawa; Yasuyoshi Chiba; Ryuichi Hirayama; Noriyuki Kijima; Manabu Kinoshita; Yoshiko Hashii; Akihiro Tsuboi; Yoshihiro Oka; Yusuke Oji; Atsushi Kumanogoh; Haruo Sugiyama; Naoki Kagawa; Haruhiko Kishima
Journal:  Neurooncol Adv       Date:  2021-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.